{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T02:41:53Z","timestamp":1789094513848,"version":"build-2803163510"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Mol Allergy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Allergic and immunologic skin diseases negatively impact the quality of life (QoL) of affected patients with detrimental consequences. Nonetheless, in everyday clinical practice the evaluation of QoL is often overlooked. Considering the increasing prevalence of atopic dermatitis, allergic contact dermatitis, hereditary angioedema, cutaneous mastocytosis, and urticaria, it is essential to determine the effects of allergic and immunologic skin diseases on QoL. A joint meeting (GET TOGETHER 2021) of the Italian Society of Allergology, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to summarize the features of the main QoL tools used in these diseases and to describe the extent of QoL impairment as well as the impact of treatments on QoL, particularly biologic therapies. The assessment of QoL in patients with allergic and immunologic skin diseases relies on generic, organ-specific and disease-specific questionnaires. While generic and organ-specific questionnaires allow comparison between different diseases, disease-specific questionnaires are designed and validated for specific cohorts: the QoL Index for Atopic Dermatitis (QoLIAD) and the Childhood Atopic Dermatitis Impact Scale (CADIS) in atopic dermatitis, the ACD-11 in allergic contact dermatitis, the Angioedema QoL Questionnaire (AE-QoL) and the Hereditary Angioedema QoL questionnaire (HAE-QoL) in hereditary angioedema, the Mastocytosis QoL Questionnaires (MCQoL e MQLQ) in cutaneous mastocytosis, and the Chronic Urticaria QoL questionnaire (CU-Q2oL) in urticaria. Among the many factors that variably contribute to QoL impairment, pruritus can represent the leading cause of patient discomfort. Biologic therapies significantly\u00a0ameliorate QoL in atopic dermatitis, hereditary angioedema, mastocytosis and chronic\u00a0urticaria. In general, adequate management strategies are essential for improving QoL in patients with allergic and immunologic skin diseases.<\/jats:p>","DOI":"10.1186\/s12948-021-00165-6","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T19:02:43Z","timestamp":1640026963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder"],"prefix":"10.1186","volume":"19","author":[{"given":"Ester","family":"Di Agosta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Baiardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrogio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Angileri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elettra","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Belluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Bonamonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Brancaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Custurone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"De Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Detoraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Di Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fant\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Mariel","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Guidolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Lamacchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Lucia","family":"Minciullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pannofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Paravisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Passante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Peroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Quecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Schettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Tarrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tramontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliviero","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"165_CR1","first-page":"84","volume":"19","author":"E Nettis","year":"2009","unstructured":"Nettis E, Aloia AM, Di Leo E, D\u2019Erasmo M, Calogiuri GF, Ferrannini A, Vacca A. Qualit\u00e0 della vita nelle malattie cutanee d\u2019interesse allergologico [Quality of life in cutaneous diseases belonging to allergological field]. It J Allergy Clin Immunol. 2009;19:84\u201391 (in italian).","journal-title":"It J Allergy Clin Immunol"},{"key":"165_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3899\/jrheum.110906","volume":"88","author":"GA Wells","year":"2011","unstructured":"Wells GA, Russell AS, Haraoui B, Bissonnette R, Ware CF. Validity of quality of life measurement tools\u2013from generic to disease-specific. J Rheumatol Suppl. 2011;88:2\u20136. https:\/\/doi.org\/10.3899\/jrheum.110906.","journal-title":"J Rheumatol Suppl"},{"issue":"1","key":"165_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12874-021-01279-w","volume":"21","author":"R Jandhyala","year":"2021","unstructured":"Jandhyala R. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC Med Res Methodol. 2021;21(1):86. https:\/\/doi.org\/10.1186\/s12874-021-01279-w.","journal-title":"BMC Med Res Methodol"},{"key":"165_CR4","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/sj.jid.5701142","volume":"127","author":"H Both","year":"2007","unstructured":"Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific healthrelated quality of life instruments. J Invest Dermatol. 2007;127:2726\u201339.","journal-title":"J Invest Dermatol"},{"key":"165_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","volume":"31","author":"CA McHorney","year":"1993","unstructured":"McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item Short- Form Health Survey (SF-36). II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247\u201363.","journal-title":"Med Care"},{"key":"165_CR6","volume-title":"Self-reported population health: an international perspective based on EQ-5D","year":"2014","unstructured":"Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Dordrecht (NL): Springer; 2014."},{"issue":"Suppl 11","key":"165_CR7","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1002\/acr.20541","volume":"63","author":"L Busija","year":"2011","unstructured":"Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQoL). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S383-412. https:\/\/doi.org\/10.1002\/acr.20541.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"165_CR8","first-page":"997","volume":"159","author":"MKA Basra","year":"2008","unstructured":"Basra MKA, Fenech R, Gatt RM, et al. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997\u20131035.","journal-title":"Br J Dermatol"},{"issue":"1","key":"165_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0190-9622(97)70210-x","volume":"37","author":"RT Anderson","year":"1997","unstructured":"Anderson RT, Rajagopalan R. Development and validation of a quality of life instrument for cutaneous diseases. J Am Acad Dermatol. 1997;37(1):41\u201350. https:\/\/doi.org\/10.1016\/s0190-9622(97)70210-x.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"165_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","volume":"9","author":"T Ratchataswan","year":"2021","unstructured":"Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract. 2021;9(3):1053\u201365.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"165_CR11","first-page":"260","volume":"50","author":"H Mozaffari","year":"2007","unstructured":"Mozaffari H, Pourpak Z, Pourseyed S, Farhoodi A, Aghamohammadi A, Movahadi A, et al. Quality of life in atopic dermatitis patients. J Microbiol Immunol Infect. 2007;50:260\u20135.","journal-title":"J Microbiol Immunol Infect"},{"key":"165_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","volume":"22","author":"CL Carrol","year":"2005","unstructured":"Carrol CL, Balkrishnam R, Feldam SR, Fleischer AB, Manuel JC. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22:192\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"11","key":"165_CR13","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1038\/jid.2012.199","volume":"132","author":"E Neri","year":"2012","unstructured":"Neri E, Agostini F, Gremigni P, Gobbi F, Casu G, Chamlin SL, Monti F. Italian validation of the Childhood Atopic Dermatitis Impact Scale: a contribution to its clinical application. J Invest Dermatol. 2012;132(11):2534\u201343. https:\/\/doi.org\/10.1038\/jid.2012.199 (Epub 2012 Jun 14).","journal-title":"J Invest Dermatol"},{"key":"165_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1399-3038.2006.00502.x","volume":"18","author":"G Ricci","year":"2007","unstructured":"Ricci G, Bendandi B, Bellini F, Patrizi A, Masi M. Atopic dermatitis: quality of life of young italian children and their families and correlation with severity score. Pediatr Allergy Immunol. 2007;18:255\u20139.","journal-title":"Pediatr Allergy Immunol"},{"key":"165_CR15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-4362.2002.01436.x","volume":"51","author":"G Kiebert","year":"2002","unstructured":"Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002;51:151\u20138.","journal-title":"Int J Dermatol"},{"issue":"6","key":"165_CR16","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/j.1365-2133.2010.10054.x","volume":"163","author":"J Schmitt","year":"2010","unstructured":"Schmitt J, Williams H, HOME Development Group. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol. 2010;163(6):1166\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10054.x.","journal-title":"Br J Dermatol"},{"key":"165_CR17","first-page":"275","volume":"150","author":"D Whalley","year":"2005","unstructured":"Whalley D, McKenna SP, Dewar AL, Erdman RA, Kohlmann T, Niero M, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol. 2005;150:275\u201383.","journal-title":"Br J Dermatol"},{"issue":"2","key":"165_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","volume":"71","author":"R Sidbury","year":"2014","unstructured":"Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF, American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327 (Epub 2014 May 9).","journal-title":"J Am Acad Dermatol"},{"key":"165_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08799-1","author":"CY Chu","year":"2020","unstructured":"Chu CY. Treatments for childhood atopic dermatitis: an update on emerging therapies. Clin Rev Allergy Immunol. 2020. https:\/\/doi.org\/10.1007\/s12016-020-08799-1.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"24","key":"165_CR20","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, SOLO 1 and SOLO 2 investigators, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"1","key":"165_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjd.17791","volume":"181","author":"JI Silverberg","year":"2019","unstructured":"Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator\u2019s Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019;181(1):80\u20137.","journal-title":"Br J Dermatol"},{"issue":"5","key":"165_CR22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/bjd.18434","volume":"182","author":"A Wollenberg","year":"2020","unstructured":"Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182(5):1120\u201335.","journal-title":"Br J Dermatol"},{"issue":"2","key":"165_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","volume":"94","author":"D Tha\u00e7i","year":"2019","unstructured":"Tha\u00e7i D, Simpson LE, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019;94(2):266\u201375.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"165_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40257-019-00478-y","volume":"21","author":"AS Paller","year":"2020","unstructured":"Paller AS, Bansal A, Simpson EL, et al. A clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119\u201331.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"165_CR25","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","volume":"35","author":"C Patruno","year":"2021","unstructured":"Patruno C, Napolitano M, Argenziano G, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"165_CR26","unstructured":"Nettis E, Ferrucci SM, Ortoncelli M, et al. Use of dupilumab for 543 adult patients with moderate-to-severe atopic dermatitis: a multicenter, retrospective study. J Investig Allergol Clin Immunol. 2020."},{"issue":"1","key":"165_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2018.10.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"165_CR28","first-page":"249","volume":"82","author":"RP Usatine","year":"2010","unstructured":"Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82(3):249\u201355.","journal-title":"Am Fam Physician"},{"issue":"2","key":"165_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clindermatol.2019.10.003","volume":"38","author":"\u00d6F Elmas","year":"2020","unstructured":"Elmas \u00d6F, Akdeniz N, Atasoy M, Karadag AS. Contact dermatitis: a great imitator. Clin Dermatol. 2020;38(2):176\u201392. https:\/\/doi.org\/10.1016\/j.clindermatol.2019.10.003 (Epub 2019 Oct 24).","journal-title":"Clin Dermatol"},{"issue":"1","key":"165_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12016-018-8713-0","volume":"56","author":"SN Bains","year":"2019","unstructured":"Bains SN, Nash P, Fonacier L. Irritant contact dermatitis. Clin Rev Allergy Immunol. 2019;56(1):99\u2013109. https:\/\/doi.org\/10.1007\/s12016-018-8713-0.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"165_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.mcna.2019.08.012","volume":"104","author":"S Nassau","year":"2020","unstructured":"Nassau S, Fonacier L. Allergic contact dermatitis. Med Clin North Am. 2020;104(1):61\u201376. https:\/\/doi.org\/10.1016\/j.mcna.2019.08.012 (Epub 2019 Oct 28).","journal-title":"Med Clin North Am"},{"issue":"5","key":"165_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/DER.0000000000000515","volume":"30","author":"N Botto","year":"2019","unstructured":"Botto N, Raffi J, Trivedi M, Ramirez F, Allen IE, Chren MM. Validating a quality-of-life instrument for allergic contact dermatitis. Dermatitis. 2019;30(5):300\u20135. https:\/\/doi.org\/10.1097\/DER.0000000000000515.","journal-title":"Dermatitis"},{"issue":"6","key":"165_CR33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/s0190-9622(03)02112-1","volume":"49","author":"DL Kadyk","year":"2003","unstructured":"Kadyk DL, McCarter K, Achen F, Belsito DV. Quality of life in patients with allergic contact dermatitis. J Am Acad Dermatol. 2003;49(6):1037\u201348. https:\/\/doi.org\/10.1016\/s0190-9622(03)02112-1.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"165_CR34","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2478\/v10001-008-0034-8","volume":"21","author":"A Potocka","year":"2008","unstructured":"Potocka A, Turczyn-Jab\u0142o\u0144ska K, Kie\u0107-Swierczy\u0144ska M. Self-image and quality of life of dermatology patients. Int J Occup Med Environ Health. 2008;21(4):309\u201317. https:\/\/doi.org\/10.2478\/v10001-008-0034-8.","journal-title":"Int J Occup Med Environ Health"},{"issue":"3","key":"165_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/DER.0000000000000542","volume":"31","author":"J Raffi","year":"2020","unstructured":"Raffi J, Elaine Allen I, Botto N. Validating responsiveness of a quality-of-life instrument for allergic contact dermatitis. Dermatitis. 2020;31(3):209\u201314. https:\/\/doi.org\/10.1097\/DER.0000000000000542.","journal-title":"Dermatitis"},{"issue":"1","key":"165_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13643-021-01687-5","volume":"10","author":"M Rocholl","year":"2021","unstructured":"Rocholl M, Ludewig M, Brakemeier C, John SM, Wilke A. Illness perceptions of adults with eczematous skin diseases: a systematic mixed studies review. Syst Rev. 2021;10(1):141. https:\/\/doi.org\/10.1186\/s13643-021-01687-5.","journal-title":"Syst Rev"},{"issue":"4","key":"165_CR37","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/DER.0000000000000192","volume":"27","author":"J Swietlik","year":"2016","unstructured":"Swietlik J, Reeder M. Current quality-of-life tools available for use in contact dermatitis. Dermatitis. 2016;27(4):176\u201385. https:\/\/doi.org\/10.1097\/DER.0000000000000192.","journal-title":"Dermatitis"},{"issue":"2","key":"165_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2310\/6620.2010.09057","volume":"21","author":"F Ayala","year":"2010","unstructured":"Ayala F, Nino M, Fabbrocini G, Panariello L, Balato N, Foti C, Tosti A, Corazza M, Valsecchi RH, Gola M, Gallo R, Guarneri F, Pigatto PD, Cristaudo A, Schena D, Musumeci ML, Stingeni L, Lisi P. Quality of life and contact dermatitis: a disease-specific questionnaire. Dermatitis. 2010;21(2):84\u201390.","journal-title":"Dermatitis"},{"key":"165_CR39","doi-asserted-by":"publisher","first-page":"3797536","DOI":"10.1155\/2019\/3797536","volume":"2019","author":"H Kalboussi","year":"2019","unstructured":"Kalboussi H, Kacem I, Aroui H, El Maalel O, Maoua M, Brahem A, El Guedri S, Chatti S, Ghariani N, Mrizak N. Impact of allergic contact dermatitis on the quality of life and work productivity. Dermatol Res Pract. 2019;2019:3797536. https:\/\/doi.org\/10.1155\/2019\/3797536.","journal-title":"Dermatol Res Pract"},{"issue":"2","key":"165_CR40","first-page":"53","volume":"18","author":"A Potocka","year":"2009","unstructured":"Potocka A, Turczyn-Jablo\u00f1ska K, Merecz D. Psychological correlates of quality of life in dermatology patients: the role of mental health and self-acceptance. Acta Dermatovenerol Alp Pannonica Adriat. 2009;18(2):53\u201362.","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat."},{"issue":"2","key":"165_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.12819","volume":"171","author":"RF Ofenloch","year":"2014","unstructured":"Ofenloch RF, Weisshaar E, Dumke AK, Molin S, Diepgen TL, Apfelbacher C. The Quality of Life in Hand Eczema Questionnaire (QOLHEQ): validation of the German version of a new disease-specific measure of quality of life for patients with hand eczema. Br J Dermatol. 2014;171(2):304\u201312. https:\/\/doi.org\/10.1111\/bjd.12819 (Epub 2014 Jun 18).","journal-title":"Br J Dermatol"},{"key":"165_CR42","doi-asserted-by":"publisher","unstructured":"Stingeni L, Bianchi L, Hansel K, Corazza M, Gallo R, Guarneri F, Patruno C, Rigano L, Romita P, Pigatto PD, Calzavara-Pinton P; \"Skin Allergy\" group of SIDeMaST and \"SIDAPA\" (Societ\u00e0 Italiana di Dermatologia Allergologica, Professionale e Ambientale). Italian Guidelines in Patch Testing - adapted from the European Society of Contact Dermatitis (ESCD). G Ital Dermatol Venereol. 2019;154(3):227\u2013253. doi: https:\/\/doi.org\/10.23736\/S0392-0488.19.06301-6. Epub 2019 Feb 4.","DOI":"10.23736\/S0392-0488.19.06301-6"},{"issue":"3","key":"165_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2310\/6620.2004.04007","volume":"15","author":"DL Kadyk","year":"2004","unstructured":"Kadyk DL, Hall S, Belsito DV. Quality of life of patients with allergic contact dermatitis: an exploratory analysis by gender, ethnicity, age, and occupation. Dermatitis. 2004;15(3):117\u201324. https:\/\/doi.org\/10.2310\/6620.2004.04007.","journal-title":"Dermatitis"},{"issue":"3","key":"165_CR44","first-page":"149","volume":"9","author":"R Rajagopalan","year":"1998","unstructured":"Rajagopalan R, Anderson RT, Sarma S, Kallal J, Retchin C, Jones J, Fowler JF Jr, Sherertz EF. An economic evaluation of patch testing in the diagnosis and management of allergic contact dermatitis. Am J Contact Dermat. 1998;9(3):149\u201354.","journal-title":"Am J Contact Dermat"},{"issue":"5","key":"165_CR45","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2016.12.011","volume":"76","author":"F Ramirez","year":"2017","unstructured":"Ramirez F, Chren MM, Botto N. A review of the impact of patch testing on quality of life in allergic contact dermatitis. J Am Acad Dermatol. 2017;76(5):1000\u20134. https:\/\/doi.org\/10.1016\/j.jaad.2016.12.011.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"165_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1046\/j.1365-2133.2002.04692.x","volume":"146","author":"KF Thomson","year":"2002","unstructured":"Thomson KF, Wilkinson SM, Sommer S, Pollock B. Eczema: quality of life by body site and the effect of patch testing. Br J Dermatol. 2002;146(4):627\u201330. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04692.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"165_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1034\/j.1600-0536.2003.00113.x","volume":"48","author":"PN Woo","year":"2003","unstructured":"Woo PN, Hay IC, Ormerod AD. An audit of the value of patch testing and its effect on quality of life. Contact Dermatitis. 2003;48(5):244\u20137. https:\/\/doi.org\/10.1034\/j.1600-0536.2003.00113.x.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"165_CR48","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1046\/j.1365-2133.2003.05601.x","volume":"149","author":"R Skoet","year":"2003","unstructured":"Skoet R, Zachariae R, Agner T. Contact dermatitis and quality of life: a structured review of the literature. Br J Dermatol. 2003;149(3):452\u20136. https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05601.x.","journal-title":"Br J Dermatol"},{"issue":"12","key":"165_CR49","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/sj.jid.5701142","volume":"127","author":"H Both","year":"2007","unstructured":"Both H, Essink-Bot ML, Busschbach J, Nijsten T. Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol. 2007;127(12):2726\u201339. https:\/\/doi.org\/10.1038\/sj.jid.5701142 (Epub 2007 Nov 8).","journal-title":"J Invest Dermatol"},{"issue":"6","key":"165_CR50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/DER.0000000000000235","volume":"27","author":"T Braunberger","year":"2016","unstructured":"Braunberger T, Lynn D, Reimer C, Doctor M, Hill MK, Mounessa J, Dunnick CA. Disease severity and quality of life measurements in contact dermatitis: a systematic review 2005\u20132015. Dermatitis. 2016;27(6):362\u201371. https:\/\/doi.org\/10.1097\/DER.0000000000000235.","journal-title":"Dermatitis"},{"issue":"3","key":"165_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000496923","volume":"235","author":"PV Chernyshov","year":"2019","unstructured":"Chernyshov PV. The evolution of quality of life assessment and use in dermatology. Dermatology. 2019;235(3):167\u201374. https:\/\/doi.org\/10.1159\/000496923 (Epub 2019 Mar 29).","journal-title":"Dermatology"},{"issue":"9","key":"165_CR52","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1111\/jdv.16742","volume":"34","author":"PV Chernyshov","year":"2020","unstructured":"Chernyshov PV, John SM, Tomas-Aragones L, Gon\u00e7alo M, Svensson A, Bewley A, Evers AWM, Szepietowski JC, Marron SE, Manolache L, Pustisek N, Suru A, Salavastru CM, Tiplica GS, Salek MS, Finlay AY. Quality of life measurement in occupational skin diseases. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Occupational Skin Disease. J Eur Acad Dermatol Venereol. 2020;34(9):1924\u201331. https:\/\/doi.org\/10.1111\/jdv.16742 (Epub 2020 Jul 13).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"165_CR53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1067\/mjd.2003.128","volume":"48","author":"MC Reilly","year":"2003","unstructured":"Reilly MC, Lavin PT, Kahler KH, Pariser DM. Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment-Chronic Hand Dermatitis questionnaire in chronic hand dermatitis. J Am Acad Dermatol. 2003;48(1):128\u201330. https:\/\/doi.org\/10.1067\/mjd.2003.128.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"165_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1600-0536.2011.01896.x","volume":"65","author":"MY Lau","year":"2011","unstructured":"Lau MY, Matheson MC, Burgess JA, Dharmage SC, Nixon R. Disease severity and quality of life in a follow-up study of patients with occupational contact dermatitis. Contact Dermatitis. 2011;65(3):138\u201345. https:\/\/doi.org\/10.1111\/j.1600-0536.2011.01896.x (Epub 2011 Jul 3).","journal-title":"Contact Dermatitis"},{"issue":"3","key":"165_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-0536.2009.01592.x","volume":"61","author":"U Matterne","year":"2009","unstructured":"Matterne U, Apfelbacher CJ, Soder S, Diepgen TL, Weisshaar E. Health-related quality of life in health care workers with work-related skin diseases. Contact Dermatitis. 2009;61(3):145\u201351. https:\/\/doi.org\/10.1111\/j.1600-0536.2009.01592.x.","journal-title":"Contact Dermatitis"},{"issue":"4","key":"165_CR56","first-page":"215","volume":"8","author":"R Rajagopalan","year":"1997","unstructured":"Rajagopalan R, Anderson R. Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis. Am J Contact Dermat. 1997;8(4):215\u201321.","journal-title":"Am J Contact Dermat"},{"issue":"2","key":"165_CR57","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/cod.12128","volume":"70","author":"MV Heisterberg","year":"2014","unstructured":"Heisterberg MV, Menn\u00e9 T, Johansen JD. Fragrance allergy and quality of life\u2014a case-control study. Contact Dermatitis. 2014;70(2):81\u20139. https:\/\/doi.org\/10.1111\/cod.12128.","journal-title":"Contact Dermatitis"},{"issue":"2","key":"165_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/cod.12153","volume":"70","author":"MV Heisterberg","year":"2014","unstructured":"Heisterberg MV, Menn\u00e9 T, Johansen JD. Fragrance allergy and quality of life\u2014development and validation of a disease-specific quality of life instrument. Contact Dermatitis. 2014;70(2):69\u201380.","journal-title":"Contact Dermatitis"},{"issue":"2","key":"165_CR59","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/cod.13252","volume":"81","author":"NH Bennike","year":"2019","unstructured":"Bennike NH, Heisterberg MS, White IR, Mahler V, Silvestre-Salvador JF, Gim\u00e9nez-Arnau A, Johansen JD. Quality of life and disease severity in dermatitis patients with fragrance allergy-A cross-sectional European questionnaire study. Contact Dermatitis. 2019;81(2):89\u201396. https:\/\/doi.org\/10.1111\/cod.13252 (Epub 2019 Apr 1).","journal-title":"Contact Dermatitis"},{"issue":"7","key":"165_CR60","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.jid.2017.02.969","volume":"137","author":"RF Ofenloch","year":"2017","unstructured":"Ofenloch RF, Oosterhaven JAF, Susitaival P, Svensson \u00c5, Weisshaar E, Minamoto K, Onder M, Schuttelaar MLA, Bulbul Baskan E, Diepgen TL, Apfelbacher C. Cross-cultural validation of the quality of life in hand eczema questionnaire (QOLHEQ). J Invest Dermatol. 2017;137(7):1454\u201360. https:\/\/doi.org\/10.1016\/j.jid.2017.02.969 (Epub 2017 Mar 1).","journal-title":"J Invest Dermatol"},{"key":"165_CR61","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/964509","volume":"2011","author":"MY Lau","year":"2011","unstructured":"Lau MY, Burgess JA, Nixon R, Dharmage SC, Matheson MC. A review of the impact of occupational contact dermatitis on quality of life. J Allergy (Cairo). 2011;2011: 964509. https:\/\/doi.org\/10.1155\/2011\/964509 (Epub 2011 Mar 16).","journal-title":"J Allergy (Cairo)"},{"issue":"1","key":"165_CR62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1034\/j.1600-0536.2001.045001017.x","volume":"45","author":"CV Hutchings","year":"2001","unstructured":"Hutchings CV, Shum KW, Gawkrodger DJ. Occupational contact dermatitis has an appreciable impact on quality of life. Contact Dermatitis. 2001;45(1):17\u201320. https:\/\/doi.org\/10.1034\/j.1600-0536.2001.045001017.x.","journal-title":"Contact Dermatitis"},{"key":"165_CR63","doi-asserted-by":"publisher","unstructured":"Simonsen AB, Sommerlund M, Deleuran M, Mortz CG, Johansen JD. Course of skin symptoms and quality of life in children referred for patch testing--a long-term follow-up study. Acta Derm Venereol. 2015;95(2):206-10. https:\/\/doi.org\/10.2340\/00015555-1911. Erratum in: Acta Derm Venereol. 2015;95(6):767-8.","DOI":"10.2340\/00015555-1911"},{"issue":"1","key":"165_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-021-00271-4","volume":"7","author":"PL Scheinman","year":"2021","unstructured":"Scheinman PL, Vocanson M, Thyssen JP, Johansen JD, Nixon RL, Dear K, Botto NC, Morot J, Goldminz AM. Contact dermatitis. Nat Rev Dis Primers. 2021;7(1):38. https:\/\/doi.org\/10.1038\/s41572-021-00271-4.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"165_CR65","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cod.13584","volume":"83","author":"J Bhatia","year":"2020","unstructured":"Bhatia J, Sarin A, Wollina U, Lotti T, Navarini AA, Mueller SM, Grabbe S, Saloga J, Rokni GR, Goldust M. Review of biologics in allergic contact dermatitis. Contact Dermatitis. 2020;83(3):179\u201381. https:\/\/doi.org\/10.1111\/cod.13584 (Epub 2020 Jun 17).","journal-title":"Contact Dermatitis"},{"issue":"1","key":"165_CR66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/205873920601900125","volume":"19","author":"N Cassano","year":"2006","unstructured":"Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol. 2006;19(1):237\u201340.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"165_CR67","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaad.2008.02.016","volume":"59","author":"D Rosmarin","year":"2008","unstructured":"Rosmarin D, Bush M, Scheinman PL. Patch testing a patient with allergic contact hand dermatitis who is taking infliximab. J Am Acad Dermatol. 2008;59(1):145\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2008.02.016 (Epub 2008 May 12).","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"165_CR68","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/DER.0000000000000409","volume":"29","author":"SR Joshi","year":"2018","unstructured":"Joshi SR, Khan DA. Effective use of dupilumab in managing systemic allergic contact dermatitis. Dermatitis. 2018;29(5):282\u20134. https:\/\/doi.org\/10.1097\/DER.0000000000000409.","journal-title":"Dermatitis"},{"issue":"1","key":"165_CR69","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2018.07.043","volume":"80","author":"BC Machler","year":"2019","unstructured":"Machler BC, Sung CT, Darwin E, Jacob SE. Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol. 2019;80(1):280-281.e1. https:\/\/doi.org\/10.1016\/j.jaad.2018.07.043 (Epub 2018 Aug 6).","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"165_CR70","first-page":"287","volume":"23","author":"P Mur Gimeno","year":"2013","unstructured":"Mur Gimeno P, Mart\u00edn Iglesias A, Lombardero Vega M, Bautista Mart\u00ednez P, Ventura LP. Occupational wheat contact dermatitis and treatment with omalizumab. J Investig Allergol Clin Immunol. 2013;23(4):287\u20138.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"165_CR71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.imlet.2018.09.008","volume":"203","author":"TG Nguyen","year":"2018","unstructured":"Nguyen TG. Immune-modulation via IgD B-cell receptor suppresses allergic skin inflammation in experimental contact hypersensitivity models despite of a Th2-favoured humoral response. Immunol Lett. 2018;203:29\u201339. https:\/\/doi.org\/10.1016\/j.imlet.2018.09.008 (Epub 2018 Sep 12).","journal-title":"Immunol Lett"},{"key":"165_CR72","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.2169\/internalmedicine.1818-18","volume":"57","author":"T Horiuchi","year":"2018","unstructured":"Horiuchi T. Hereditary angioedema from 1888 to 2018\u2014progress and problems. Intern Med. 2018;57:3065\u20136.","journal-title":"Intern Med"},{"key":"165_CR73","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1808012","volume":"382","author":"PJ Busse","year":"2020","unstructured":"Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382:1136\u201348.","journal-title":"N Engl J Med"},{"key":"165_CR74","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3389\/fmed.2017.00245","volume":"4","author":"H Longhurst","year":"2018","unstructured":"Longhurst H. Optimum use of acute treatments for hereditary angioedema: evidence-based expert consensus. Front Med (Lausanne). 2018;4:245.","journal-title":"Front Med (Lausanne)"},{"key":"165_CR75","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14680","volume":"76","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Weller K, Magerl M, et al. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. Allergy. 2021;76:1188\u201398.","journal-title":"Allergy"},{"key":"165_CR76","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/all.13384","volume":"73","author":"M Maurer","year":"2018","unstructured":"Maurer M, Magerl M, Ansotegui I, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73:1575\u201396.","journal-title":"Allergy"},{"key":"165_CR77","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1111\/all.12380","volume":"69","author":"M Cicardi","year":"2014","unstructured":"Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602\u201316.","journal-title":"Allergy"},{"key":"165_CR78","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.iac.2017.04.005","volume":"37","author":"T Caballero","year":"2017","unstructured":"Caballero T, Prior N. Burden of illness and quality-of-life measures in angioedema conditions. Immunol Allergy Clin North Am. 2017;37:597\u2013616.","journal-title":"Immunol Allergy Clin North Am"},{"key":"165_CR79","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/all.12007","volume":"67","author":"K Weller","year":"2012","unstructured":"Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire. Allergy. 2012;67:1289\u201398.","journal-title":"Allergy"},{"key":"165_CR80","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/all.12900","volume":"71","author":"K Weller","year":"2016","unstructured":"Weller K, Magerl M, Peveling-Oberhag A, et al. The Angioedema Quality of Life Questionnaire (AE-QoL)\u2014assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016;71:1203\u20139.","journal-title":"Allergy"},{"issue":"21","key":"165_CR81","first-page":"00048","volume":"S1323\u20138930","author":"S Morioke","year":"2021","unstructured":"Morioke S, Takahagi S, Kawano R, et al. A validation study of the Japanese version of the Angioedema Activity Score (AAS) and the Angioedema Quality of Life Questionnaire (AE-QoL). Allergol Int. 2021;S1323\u20138930(21):00048\u201354.","journal-title":"Allergol Int"},{"key":"165_CR82","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12955-019-1229-3","volume":"17","author":"K Kulthanan","year":"2019","unstructured":"Kulthanan K, Chularojanamontri L, Rujitharanawong C, et al. Angioedema quality of life questionnaire (AE-QoL)\u2014interpretability and sensitivity to change. Health Qual Life Outcomes. 2019;17:160.","journal-title":"Health Qual Life Outcomes"},{"key":"165_CR83","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fmed.2017.00212","volume":"4","author":"A Bygum","year":"2017","unstructured":"Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front Med (Lausanne). 2017;4:212.","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl 3","key":"165_CR84","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.13200","volume":"29","author":"K Weller","year":"2015","unstructured":"Weller K, Zuberbier T, Maurer M. Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. J Eur Acad Dermatol Venereol. 2015;29(Suppl 3):38\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"165_CR85","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.13397","volume":"73","author":"T Zuberbier","year":"2018","unstructured":"Zuberbier T, Aberer W, Asero R, et al. The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393\u2013414.","journal-title":"Allergy"},{"key":"165_CR86","doi-asserted-by":"publisher","DOI":"10.1111\/all.15090","author":"T Zuberbier","year":"2021","unstructured":"Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, et al. The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2021. https:\/\/doi.org\/10.1111\/all.15090.","journal-title":"Allergy"},{"key":"165_CR87","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1477-7525-10-82","volume":"10","author":"N Prior","year":"2012","unstructured":"Prior N, Remor E, G\u00f3mez-Traseira C, et al. Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health Qual Life Outcomes. 2012;10:82.","journal-title":"Health Qual Life Outcomes"},{"key":"165_CR88","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.jaip.2015.12.010","volume":"4","author":"N Prior","year":"2016","unstructured":"Prior N, Remor E, P\u00e9rez-Fern\u00e1ndez E, et al. Psychometric field study of Hereditary Angioedema Quality of Life questionnaire for adults: HAE-QoL. J Allergy Clin Immunol Pract. 2016;4:464-73.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"165_CR89","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jaip.2018.11.042","volume":"7","author":"PJ Busse","year":"2019","unstructured":"Busse PJ, Christiansen SC, Birmingham JM, et al. Development of a health-related quality of life instrument for patients with hereditary angioedema living in the United States. J Allergy Clin Immunol Pract. 2019;7:1679-83.e7.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"165_CR90","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2500\/aap.2014.35.3783","volume":"35","author":"WR Lumry","year":"2014","unstructured":"Lumry WR, Miller DP, Newcomer S, et al. Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy Asthma Proc. 2014;35:371\u20136.","journal-title":"Allergy Asthma Proc"},{"key":"165_CR91","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","volume":"6","author":"WR Lumry","year":"2018","unstructured":"Lumry WR, Craig T, Zuraw B, et al. Health-related quality of life with subcutaneous c1-inhibitor for prevention of attacks of hereditary angioedema. J Allergy Clin Immunol Pract. 2018;6:1733-41.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"165_CR92","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13023-020-01658-4","volume":"16","author":"WR Lumry","year":"2021","unstructured":"Lumry WR, Zuraw B, Cicardi M, et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet J Rare Dis. 2021;16:86.","journal-title":"Orphanet J Rare Dis"},{"key":"165_CR93","doi-asserted-by":"publisher","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","volume":"289","author":"JA Kenniston","year":"2014","unstructured":"Kenniston JA, Faucette RR, Martik D, et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. J Biol Chem. 2014;289:23596\u2013608.","journal-title":"J Biol Chem"},{"key":"165_CR94","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","volume":"376","author":"A Banerji","year":"2017","unstructured":"Banerji A, Busse P, Shennak M, et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 2017;376:717\u201328.","journal-title":"N Engl J Med"},{"key":"165_CR95","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","volume":"113","author":"Y Chyung","year":"2014","unstructured":"Chyung Y, Vince B, Iarrobino R, et al. A phase 1 study investigating DX-2930 in healthy subjects. Ann Allergy Asthma Immunol. 2014;113:460\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"165_CR96","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","volume":"320","author":"A Banerji","year":"2018","unstructured":"Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320:2108\u201321.","journal-title":"JAMA"},{"key":"165_CR97","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13601-017-0172-9","volume":"7","author":"MA Riedl","year":"2017","unstructured":"Riedl MA, Bernstein JA, Craig T, et al. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. Clin Transl Allergy. 2017;7:36.","journal-title":"Clin Transl Allergy"},{"key":"165_CR98","doi-asserted-by":"publisher","unstructured":"Lumry WR, Maurer M, Megerl M, et al. Long-term lanadelumab treatment improves health-related quality of life: HELP open-label extension study interim findings. ACAAI Annual Meeting 2019. Abstract #P156. https:\/\/doi.org\/10.1016\/j.anai.2019.08.260.","DOI":"10.1016\/j.anai.2019.08.260"},{"key":"165_CR99","doi-asserted-by":"crossref","unstructured":"Craig TJ, Soteres D, Anderson J, et al. Quality of life of hereditary angioedema (HAE) patients with medical history of depression\/anxiety receiving lanadelumab. ACAAI Annual Meeting 2020. Poster #P163.","DOI":"10.1016\/j.anai.2020.08.096"},{"key":"165_CR100","doi-asserted-by":"publisher","first-page":"978","DOI":"10.36849\/JDD.2020.5269","volume":"19","author":"J Hahn","year":"2020","unstructured":"Hahn J, Trainotti S, Wigand MC, et al. Prospective analysis in patients with HAE under prophylaxis with lanadelumab: a real-life experience. J Drugs Dermatol. 2020;19:978\u201383.","journal-title":"J Drugs Dermatol"},{"key":"165_CR101","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.anai.2015.01.003","volume":"114","author":"MA Riedl","year":"2015","unstructured":"Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol. 2015;114:281-8.e287.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"165_CR102","doi-asserted-by":"crossref","unstructured":"Rossignol J, Polivka L, Maouche-Chr\u00e9tien L, Frenzel L, Dubreuil P, Hermine O. Recent advances in the understanding and therapeutic management of mastocytosis. F1000Res. 2019;8:F1000 Faculty Rev-1961.","DOI":"10.12688\/f1000research.19463.1"},{"key":"165_CR103","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","volume":"129","author":"P Valent","year":"2017","unstructured":"Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420\u20137.","journal-title":"Blood"},{"issue":"7","key":"165_CR104","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/all.13425","volume":"73","author":"F Siebenhaar","year":"2018","unstructured":"Siebenhaar F, Sander B, Ho LHT, Ellrich A, Maurer M, Weller K. Development and validation of the mastocytosis activity score. Allergy. 2018;73(7):1489\u201396. https:\/\/doi.org\/10.1111\/all.13425 (Epub 2018 Mar 1).","journal-title":"Allergy"},{"issue":"11","key":"165_CR105","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/all.12920","volume":"71","author":"B van Anrooij","year":"2016","unstructured":"van Anrooij B, Kluin-Nelemans JC, Safy M, Flokstra-de Blok BMJ, Oude Elberink JNG. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy. 2016;71(11):1585\u201393.","journal-title":"Allergy"},{"issue":"4","key":"165_CR106","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.anai.2019.12.020","volume":"124","author":"MR Vermeiren","year":"2020","unstructured":"Vermeiren MR, Kranenburg LW, van Daele PLA, van Wijk GR, Hermans MAW. Psychological functioning and quality of life in patients with mastocytosis: a cross-sectional study. Ann Allergy Asthma Immunol. 2020;124(4):373-378.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"165_CR107","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","volume":"2","author":"S Jennings","year":"2014","unstructured":"Jennings S, Russell N, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract. 2014;2:70\u20136.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"165_CR108","first-page":"525","volume":"9","author":"A Nowak","year":"2011","unstructured":"Nowak A, Gibbs BF, Amon U. Pre-inpatient evaluation on quality and impact of care in systemic mastocytosis and the influence of hospital stay periods from the perspective of patients: a pilot study. J Dtsch Dermatol Ges. 2011;9(7):525\u201332 (English, German).","journal-title":"J Dtsch Dermatol Ges"},{"key":"165_CR109","doi-asserted-by":"publisher","first-page":"e2266","DOI":"10.1371\/journal.pone.0002266","volume":"3","author":"O Hermine","year":"2008","unstructured":"Hermine O, Lortholary O, Leventhal PS, et al. Case-control cohort study of patient\u2019s perceptions of disability in mastocytosis. PLoS ONE. 2008;3:e2266.","journal-title":"PLoS ONE"},{"issue":"7\u20138","key":"165_CR110","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/jocn.14676","volume":"28","author":"B Jensen","year":"2019","unstructured":"Jensen B, Broesby-Olsen S, Bindslev-Jensen C, Nielsen DS. Everyday life and mastocytosis from a patient perspective-a qualitative study. J Clin Nurs. 2019;28(7\u20138):1114\u201324.","journal-title":"J Clin Nurs"},{"issue":"21","key":"165_CR111","doi-asserted-by":"publisher","first-page":"00565","DOI":"10.1016\/j.jaip.2021.04.059","volume":"S2213\u20132198","author":"S Pulfer","year":"2021","unstructured":"Pulfer S, Ziehfreund S, Gebhard J, Hindelang B, Biedermann T, Brockow K, Zink A. Health-related quality of life and influencing factors in adults with nonadvanced mastocytosis\u2014a cross-sectional study and qualitative approach. J Allergy Clin Immunol Pract. 2021;S2213\u20132198(21):00565\u201371. https:\/\/doi.org\/10.1016\/j.jaip.2021.04.059.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"165_CR112","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/all.12842","volume":"71","author":"F Siebenhaar","year":"2016","unstructured":"Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, Wagner N, Martus P, Carter MC, Metcalfe DD, Church MK, Maurer M, Weller K. Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy. 2016;71(6):869\u201377.","journal-title":"Allergy"},{"issue":"3","key":"165_CR113","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.iac.2018.04.006","volume":"38","author":"SV Jennings","year":"2018","unstructured":"Jennings SV, Slee VM, Zack RM, Verstovsek S, George TI, Shi H, Lee P, Castells MC. Patient perceptions in mast cell disorders. Immunol Allergy Clin North Am. 2018;38(3):505\u201325.","journal-title":"Immunol Allergy Clin North Am"},{"key":"165_CR114","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1038\/mp.2015.216","volume":"21","author":"S Georgin-Lavialle","year":"2016","unstructured":"Georgin-Lavialle S, Moura DS, Salvador A, et al. Mast cells\u2019 involvement in inflamamtion pathways linked to depression: evidence in mastocytosis. Mol Psychiatry. 2016;21:1511\u20136.","journal-title":"Mol Psychiatry"},{"issue":"7","key":"165_CR115","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/all.12159","volume":"68","author":"F Siebenhaar","year":"2013","unstructured":"Siebenhaar F, F\u00f6rtsch A, Krause K, Weller K, Metz M, Magerl M, Martus P, Church MK, Maurer M. Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. Allergy. 2013;68(7):949\u201352. https:\/\/doi.org\/10.1111\/all.12159 (Epub 2013 Jun 4).","journal-title":"Allergy"},{"issue":"2","key":"165_CR116","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","volume":"146","author":"K Hartmann","year":"2020","unstructured":"Hartmann K, Gotlib J, Akin C, Hermine O, Awan FT, Hexner E, Mauro MJ, Menssen HD, Redhu S, Knoll S, Sotlar K, George TI, Horny HP, Valent P, Reiter A, Kluin-Nelemans HC. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020;146(2):356-366.e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"165_CR117","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","volume":"50","author":"F Jendoubi","year":"2020","unstructured":"Jendoubi F, Gaudenzio N, Gallini A, Negretto M, Paul C, Bulai LC. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50(6):654\u201361.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"165_CR118","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/all.13237","volume":"73","author":"S Broesby-Olsen","year":"2018","unstructured":"Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, Siebenhaar F, M\u00f8ller MB, Kristensen TK, Bindslev-Jensen C, Mastocytosis Centre Odense University Hospital (MastOUH). Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy. 2018;73(1):230\u20138.","journal-title":"Allergy"},{"key":"165_CR119","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12948-020-00123-8","volume":"18","author":"E Nettis","year":"2020","unstructured":"Nettis E, Foti C, Ambrifi M, Baiardini I, Bianchi L, Borghi A, et al. Urticaria: recommendations from the Italian Society of allergology, asthma and clinical immunology and the Italian society of allergological, occupational and environmental dermatology. Clin Mol Allergy. 2020;18:8. https:\/\/doi.org\/10.1186\/s12948-020-00123-8.","journal-title":"Clin Mol Allergy"},{"issue":"2","key":"165_CR120","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/all.14037","volume":"75","author":"J Fricke","year":"2020","unstructured":"Fricke J, \u00c1vila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423\u201332. https:\/\/doi.org\/10.1111\/all.14037 (Epub 2019 Oct 11).","journal-title":"Allergy"},{"key":"165_CR121","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1398-9995.2011.02580.x","volume":"66","author":"I Baiardini","year":"2011","unstructured":"Baiardini I, Braido F, Bindslev-Jensen C, et al. Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. Allergy. 2011;66:840\u20134.","journal-title":"Allergy"},{"key":"165_CR122","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","volume":"136","author":"BF O'Donnell","year":"1997","unstructured":"O\u2019Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136:197\u2013201.","journal-title":"Br J Dermatol"},{"issue":"4","key":"165_CR123","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaip.2017.10.001","volume":"6","author":"T Hawro","year":"2018","unstructured":"Hawro T, Ohanyan T, Schoepke N, Metz M, Peveling-Oberhag A, Staubach P, et al. The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1. https:\/\/doi.org\/10.1016\/j.jaip.2017.10.001.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"165_CR124","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","volume":"133","author":"K Weller","year":"2014","unstructured":"Weller K, Groffik A, Church MK, Hawro T, Krause K, Metz M, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-72.e6. https:\/\/doi.org\/10.1016\/j.jaci.2013.12.1076.","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"165_CR125","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/all.12209","volume":"68","author":"K Weller","year":"2013","unstructured":"Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development, validation, and initial results of the Angioedema Activity Score. Allergy. 2013;68(9):1185\u201392. https:\/\/doi.org\/10.1111\/all.12209 (Epub 2013 Aug 6).","journal-title":"Allergy"},{"issue":"8","key":"165_CR126","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/all.12900","volume":"71","author":"K Weller","year":"2016","unstructured":"Weller K, Magerl M, Peveling-Oberhag A, Martus P, Staubach P, Maurer M. The Angioedema Quality of Life Questionnaire (AE-QoL)\u2014assessment of sensitivity to change and minimal clinically important difference. Allergy. 2016;71(8):1203\u20139. https:\/\/doi.org\/10.1111\/all.12900 (Epub 2016 Jun 13).","journal-title":"Allergy"},{"key":"165_CR127","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"165_CR128","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/all.13209","volume":"72","author":"M Maurer","year":"2017","unstructured":"Maurer M, Abuzakouk M, B\u00e9rard F, Canonica W, Oude Elberink H, Gim\u00e9nez-Arnau A, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005\u201316. https:\/\/doi.org\/10.1111\/all.13209 (Epub 2017 Jul 10).","journal-title":"Allergy"},{"issue":"7","key":"165_CR129","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2340\/00015555-2941","volume":"98","author":"L Curto-Barredo","year":"2018","unstructured":"Curto-Barredo L, Archilla L, Vives G, Pujol R, Gim\u00e9nez-Arnau A. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98(7):641\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"165_CR130","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jaad.2018.01.023","volume":"79","author":"C Antia","year":"2018","unstructured":"Antia C, Baquerizo K, Korman A, Alikhan A, Bernstein JA. Urticaria: a comprehensive review. J Am Acad Dermatol. 2018;79(4):617\u201333.","journal-title":"J Am Acad Dermatol"},{"key":"165_CR131","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ad.2016.12.012","volume":"108","author":"I Marin-Cabanas","year":"2017","unstructured":"Marin-Cabanas I, Berbegal-de Gracia L, Leon-Marrero F, et al. Management of chronic spontaneous urticaria in routine clinical practice following the EAACI\/GA2LEN\/EDF\/WAO Guidelines. Actas Dermosifiliogr. 2017;108:346\u201353.","journal-title":"Actas Dermosifiliogr"},{"key":"165_CR132","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/bjd.14768","volume":"175","author":"S Guillen-Aguinaga","year":"2016","unstructured":"Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and. Br J Dermatol. 2016;175:1153\u201365.","journal-title":"Br J Dermatol"},{"key":"165_CR133","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/bcp.12421","volume":"78","author":"M Farre","year":"2014","unstructured":"Farre M, Perez-Mana C, Papaseit E, Menoyo E, P\u00e9rez M, Martin S, et al. Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers. Br J Clin Pharmacol. 2014;78:970\u201380.","journal-title":"Br J Clin Pharmacol"},{"key":"165_CR134","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.alit.2016.08.004","volume":"66","author":"M Hide","year":"2017","unstructured":"Hide M, Yagami A, Togawa M, Saito A, Furue M. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: a multi- center, randomized, double-blind, placebo-controlled, parallel-group phase II\/III study. Allergol Int. 2017;66:317\u201325.","journal-title":"Allergol Int"},{"key":"165_CR135","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/1346-8138.13644","volume":"44","author":"A Yagami","year":"2017","unstructured":"Yagami A, Furue M, Togawa M, Saito A, Hide M. One-year safety and e cacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases. J Dermatol. 2017;44:375\u201385.","journal-title":"J Dermatol"},{"issue":"3","key":"165_CR136","first-page":"820","volume":"22","author":"A Demonte","year":"2018","unstructured":"Demonte A, Guanti MB, Liberati S, Biffi A, Fernando F, Fainello M, Pepe P. Bilastine safety in drivers who need antihistamines: new evidence from high-speed simulator driving test on allergic patients. Eur Rev Med Pharmacol Sci. 2018;22(3):820\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"165_CR137","doi-asserted-by":"publisher","first-page":"e13946","DOI":"10.1111\/dth.13946","volume":"33","author":"I Podder","year":"2020","unstructured":"Podder I, Das A, Ghosh S, Biswas D, Sengupta S, Chowdhury SN. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: a double-blind, parallel group, randomized controlled trial. Dermatol Ther. 2020;33(6):e13946.","journal-title":"Dermatol Ther"},{"issue":"4","key":"165_CR138","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1398-9995.2009.02217.x","volume":"65","author":"T Zuberbier","year":"2010","unstructured":"Zuberbier T, Oanta A, Bogacka E, Medina I, Wesel F, Uhl P, Ant\u00e9para I, J\u00e1uregui I, Valiente R. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Bilastine Int Working Group. Allergy. 2010;65(4):516\u201328.","journal-title":"Allergy"},{"key":"165_CR139","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","volume":"137","author":"ZT Zhao","year":"2016","unstructured":"Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742\u201350.","journal-title":"J Allergy Clin Immunol"},{"key":"165_CR140","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jaci.2011.06.010","volume":"128","author":"S Saini","year":"2011","unstructured":"Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567\u201373.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"165_CR141","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.anai.2013.12.005","volume":"112","author":"G Sussman","year":"2014","unstructured":"Sussman G, Hebert J, Barron C, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112(2):170\u20134.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"165_CR142","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jdermsci.2013.08.011","volume":"73","author":"M Metz","year":"2014","unstructured":"Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57\u201362.","journal-title":"J Dermatol Sci"},{"key":"165_CR143","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.anai.2016.06.024","volume":"117","author":"JL Zazzali","year":"2016","unstructured":"Zazzali JL, Kaplan A, Maurer M, et al. Angioedema in the omalizumab chronic idiopathic\/spontaneous urticaria pivotal studies. Ann Allergy Asthma Immunol. 2016;117:370\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"165_CR144","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/jdv.14384","volume":"31","author":"AY Finlay","year":"2017","unstructured":"Finlay AY, Kaplan AP, Beck LA, Antonova EN, Balp MM, Zazzali J, Khalil S, Maurer M. Omalizumab substantially improves dermatology-related quality of life in patients with chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2017;31(10):1715\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"165_CR145","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/all.14547","volume":"76","author":"I Agache","year":"2021","unstructured":"Agache I, Rocha C, Pereira A, Song Y, Alonso-Coello P, Sol\u00e0 I, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76:59\u201370.","journal-title":"Allergy"},{"issue":"1","key":"165_CR146","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","volume":"155","author":"MD Tharp","year":"2019","unstructured":"Tharp MD, Bernstein JA, Kavati A, et al. Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (spontaneous) urticaria: a meta-analysis of \u201creal-world\u201d evidence. JAMA Dermatol. 2019;155(1):29\u201338. https:\/\/doi.org\/10.1001\/jamadermatol.2018.3447.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"165_CR147","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","volume":"18","author":"JA Bernstein","year":"2018","unstructured":"Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u2018real-world\u2019 evidence. Expert Opin Biol Ther. 2018;18(4):425\u201348. https:\/\/doi.org\/10.1080\/14712598.2018.1438406.","journal-title":"Expert Opin Biol Ther"},{"key":"165_CR148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","volume":"59","author":"M Metz","year":"2020","unstructured":"Metz M, Vadsz Z, Kocat\u00f9rk E, Gimenez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59:38\u201345.","journal-title":"Clin Rev Allergy Immunol"},{"key":"165_CR149","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","volume":"66","author":"M Maurer","year":"2011","unstructured":"Maurer M, Weller K, Bindslev-Jensen C, Gim\u00e9nez-Arnau A, Bousquet P, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticarial. A GA2LEN task force report 1. Allergy. 2011;66:317\u201330.","journal-title":"Allergy"},{"key":"165_CR150","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2014.306","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1-antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67\u201375.","journal-title":"J Invest Dermatol"},{"key":"165_CR151","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924\u20139354.","journal-title":"N Engl J Med"},{"key":"165_CR152","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/all.13339","volume":"73","author":"P Staubach","year":"2018","unstructured":"Staubach P, Metz M, Chapman-Rothe N, Sieder C, Br\u00e4utigam M, Maurer M, et al. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data. Allergy. 2018;73:576\u201384.","journal-title":"Allergy"},{"key":"165_CR153","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/jdv.14075","volume":"31","author":"M Maurer","year":"2017","unstructured":"Maurer M, Sofen H, Ortiz B, Kianifard F, Gabriel S, Bernstein J. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic\/spontaneous urticaria: analyses according to the presence or absence of angioedema. J Eur Acad Dermatol Venereol. 2017;31:1056\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"165_CR154","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.anai.2015.02.007","volume":"114","author":"J Azofra","year":"2015","unstructured":"Azofra J, Diaz C, Antepara I, Jauregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 2015;114:418\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"165_CR155","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1046\/j.1365-2133.2000.03664.x","volume":"143","author":"CE Grattan","year":"2000","unstructured":"Grattan CE, O\u2019Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic \u2018idiopathic\u2019 urticaria. Br J Dermatol. 2000;143:365\u201372.","journal-title":"Br J Dermatol"},{"key":"165_CR156","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.jaad.2006.04.078","volume":"55","author":"GA Vena","year":"2006","unstructured":"Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2006;55:705\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"165_CR157","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.jaip.2017.07.017","volume":"6","author":"K Kulthanan","year":"2018","unstructured":"Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586\u201399.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"165_CR158","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13223-015-0088-7","volume":"11","author":"S Savic","year":"2015","unstructured":"Savic S, Marsland A, McKay D, Ardern-Jones MR, Leslie T, Somenzi O, et al. Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy Asthma Clin Immunol. 2015;11(1):21.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"1","key":"165_CR159","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.anai.2019.08.014","volume":"124","author":"P Kolkhir","year":"2020","unstructured":"Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2\u201312.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"14","key":"165_CR160","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","volume":"381","author":"M Maurer","year":"2019","unstructured":"Maurer M, Gim\u00e9nez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"165_CR161","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","volume":"7","author":"JK Lee","year":"2019","unstructured":"Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019;7(5):1659\u201361.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"165_CR162","first-page":"e86","volume":"32","author":"M Maurer","year":"2018","unstructured":"Maurer M, Altrichter S, Metz M, Zuberbier MKT, Church MK, Bergmann KC. Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. JEADV. 2018;32:e86\u2013121.","journal-title":"JEADV"}],"container-title":["Clinical and Molecular Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-021-00165-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12948-021-00165-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-021-00165-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T05:37:59Z","timestamp":1676007479000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalmolecularallergy.biomedcentral.com\/articles\/10.1186\/s12948-021-00165-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":162,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["165"],"URL":"https:\/\/doi.org\/10.1186\/s12948-021-00165-6","relation":{},"ISSN":["1476-7961"],"issn-type":[{"value":"1476-7961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"4 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declares that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}